- Home
- RDHL vs EVAX Comparison
RDHL vs EVAX Comparison
Compare RDHL & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- EVAX
- Stock Information
- Founded
- RDHL 2009
- EVAX 2008
- Country
- RDHL Israel
- EVAX Denmark
- Employees
- RDHL N/A
- EVAX N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RDHL Health Care
- EVAX Health Care
- Exchange
- RDHL Nasdaq
- EVAX Nasdaq
- Market Cap
- RDHL 3.9M
- EVAX 17.8M
- IPO Year
- RDHL N/A
- EVAX 2021
- Fundamental
- Price
- RDHL $1.52
- EVAX $2.94
- Analyst Decision
- RDHL
- EVAX Strong Buy
- Analyst Count
- RDHL 0
- EVAX 2
- Target Price
- RDHL N/A
- EVAX $10.00
- AVG Volume (30 Days)
- RDHL 88.3K
- EVAX 89.0K
- Earning Date
- RDHL 09-05-2025
- EVAX 10-30-2025
- Dividend Yield
- RDHL N/A
- EVAX N/A
- EPS Growth
- RDHL N/A
- EVAX N/A
- EPS
- RDHL N/A
- EVAX N/A
- Revenue
- RDHL $9,550,000.00
- EVAX $3,176,000.00
- Revenue This Year
- RDHL $381.91
- EVAX N/A
- Revenue Next Year
- RDHL N/A
- EVAX N/A
- P/E Ratio
- RDHL N/A
- EVAX N/A
- Revenue Growth
- RDHL 157.62
- EVAX 1042.45
- 52 Week Low
- RDHL $1.06
- EVAX $1.20
- 52 Week High
- RDHL $11.70
- EVAX $17.20
- Technical
- Relative Strength Index (RSI)
- RDHL 54.73
- EVAX 52.67
- Support Level
- RDHL $1.47
- EVAX $2.81
- Resistance Level
- RDHL $1.60
- EVAX $3.04
- Average True Range (ATR)
- RDHL 0.08
- EVAX 0.20
- MACD
- RDHL 0.04
- EVAX -0.00
- Stochastic Oscillator
- RDHL 78.95
- EVAX 71.83
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.